Ningbo Menovo Pharm Co Ltd - Asset Resilience Ratio
Ningbo Menovo Pharm Co Ltd (603538) has an Asset Resilience Ratio of 2.69% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 603538 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Ningbo Menovo Pharm Co Ltd's Asset Resilience Ratio has changed over time. See Ningbo Menovo Pharm Co Ltd book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Ningbo Menovo Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Ningbo Menovo Pharm Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥127.52 Million | 2.69% |
| Total Liquid Assets | CN¥127.52 Million | 2.69% |
Asset Resilience Insights
- Limited Liquidity: Ningbo Menovo Pharm Co Ltd maintains only 2.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ningbo Menovo Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ningbo Menovo Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Ningbo Menovo Pharm Co Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Ningbo Menovo Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.32% | CN¥154.44 Million ≈ $22.60 Million |
CN¥4.65 Billion ≈ $680.62 Million |
-2.75pp |
| 2023-12-31 | 6.07% | CN¥268.65 Million ≈ $39.31 Million |
CN¥4.42 Billion ≈ $647.30 Million |
+1.15pp |
| 2022-12-31 | 4.92% | CN¥217.38 Million ≈ $31.81 Million |
CN¥4.42 Billion ≈ $646.71 Million |
-4.36pp |
| 2021-12-31 | 9.28% | CN¥371.38 Million ≈ $54.34 Million |
CN¥4.00 Billion ≈ $585.54 Million |
+4.93pp |
| 2020-12-31 | 4.35% | CN¥133.14 Million ≈ $19.48 Million |
CN¥3.06 Billion ≈ $448.17 Million |
+0.50pp |
| 2019-12-31 | 3.85% | CN¥100.60 Million ≈ $14.72 Million |
CN¥2.61 Billion ≈ $382.51 Million |
-12.80pp |
| 2017-12-31 | 16.65% | CN¥252.00 Million ≈ $36.88 Million |
CN¥1.51 Billion ≈ $221.50 Million |
+16.61pp |
| 2012-12-31 | 0.04% | CN¥350.50K ≈ $51.29K |
CN¥831.58 Million ≈ $121.69 Million |
-0.43pp |
| 2011-12-31 | 0.48% | CN¥3.37 Million ≈ $493.82K |
CN¥709.97 Million ≈ $103.89 Million |
-- |
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more